In regulated industries like healthcare, the years required to build partnerships, navigate compliance, and establish trust create a significant moat. This defensibility protects specialized application-layer startups from being overrun by large, horizontal model providers who cannot easily replicate these deep, industry-specific relationships.

While patents are important, a pharmaceutical giant's most durable competitive advantage is its ability to navigate complex global regulatory systems. This 'regulatory know-how' is a massive barrier to entry that startups cannot easily replicate, forcing them into acquisition by incumbents.

While GDPR aimed to protect consumer data, it raised the cost of doing business so high that only tech giants could afford full compliance. This created a regulatory moat, disadvantaging European startups and unintentionally cementing the market power of the very companies the regulation was meant to police.

Unlike US startups serving one large market, Legora's Swedish origins necessitated immediate expansion into different countries with unique languages and laws. This built a core competency in multi-market operations, making global expansion a natural next step.

Beyond technology, Booking's CEO highlights the complex global regulatory framework for travel as a major hurdle. For startups wanting to act as a merchant of record, navigating these rules is a costly and complex challenge that incumbents with scale are better equipped to handle, creating a non-obvious moat.

While fast-moving, unregulated competitors like FTX garner hype, a deliberate, compliance-first approach builds a more resilient and defensible business in sectors like finance. This unsexy path is the key to building a lasting, mainstream company with a strong regulatory moat.

To maintain high velocity, Robinhood integrates legal and compliance partners into product development from the very beginning. By making them co-owners of the product vision, they become creative problem-solvers rather than end-stage blockers, which is crucial for shipping quickly in a regulated industry.

The co-founder argues that the time-consuming, unscalable tasks of the early years—like deep research and on-site deployments—are what create a company's durable competitive advantage. He suggests businesses achieving hyper-growth too quickly may lack this defensible moat, making their success fleeting.

Regulatory readiness is one of the most underappreciated value drivers in MedTech M&A. An acquirer will pay a premium for a target with a mature regulatory infrastructure, as this "organizational muscle" can save them 2-3 years versus building it from scratch.